GSK Anticipates Slower Uptake of RSV Vaccine Compared to Shingles Shot

GlaxoSmithKline CEO Emma Walmsley expects the uptake of the company's new RSV vaccine to start slower than its shingles shot, but believes it will drive future sales. The RSV vaccine recently received approval in the US and EU for adults 60 and older, and GSK plans to roll it out this fall. While the company has not provided revenue estimates for the RSV shot, it expects overall vaccine revenue to increase by a "mid-teens" percentage from last year. GSK's shingles shot, called Shingrix, has been a top-selling drug for the company and gained over 90% of the US market share for shingles vaccines within five months of its launch. Investors are hopeful that both the shingles and RSV shots will help offset patent expirations for GSK's HIV drugs in the future.